MX2009013672A - Tratamiento de enfermedades y trastornos utilizando celulas formadoras de colonias de autorenovacion cultivadas y expandidas in vitro. - Google Patents

Tratamiento de enfermedades y trastornos utilizando celulas formadoras de colonias de autorenovacion cultivadas y expandidas in vitro.

Info

Publication number
MX2009013672A
MX2009013672A MX2009013672A MX2009013672A MX2009013672A MX 2009013672 A MX2009013672 A MX 2009013672A MX 2009013672 A MX2009013672 A MX 2009013672A MX 2009013672 A MX2009013672 A MX 2009013672A MX 2009013672 A MX2009013672 A MX 2009013672A
Authority
MX
Mexico
Prior art keywords
disorders
diseases
self
treatment
colony forming
Prior art date
Application number
MX2009013672A
Other languages
English (en)
Spanish (es)
Inventor
Gene Kopen
Joseph Wagner
Vanessa Ragaglia
Baron Heimbach
Richard S Gore
Original Assignee
Garnet Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garnet Biotherapeutics Inc filed Critical Garnet Biotherapeutics Inc
Publication of MX2009013672A publication Critical patent/MX2009013672A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
MX2009013672A 2007-06-15 2008-06-16 Tratamiento de enfermedades y trastornos utilizando celulas formadoras de colonias de autorenovacion cultivadas y expandidas in vitro. MX2009013672A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US92915107P 2007-06-15 2007-06-15
US92915207P 2007-06-15 2007-06-15
US95520407P 2007-08-10 2007-08-10
US99609307P 2007-11-01 2007-11-01
PCT/US2008/007488 WO2008156728A1 (en) 2007-06-15 2008-06-16 Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro

Publications (1)

Publication Number Publication Date
MX2009013672A true MX2009013672A (es) 2010-03-30

Family

ID=40156544

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013672A MX2009013672A (es) 2007-06-15 2008-06-16 Tratamiento de enfermedades y trastornos utilizando celulas formadoras de colonias de autorenovacion cultivadas y expandidas in vitro.

Country Status (14)

Country Link
US (5) US8354370B2 (enExample)
EP (1) EP2171043B1 (enExample)
JP (1) JP2010529987A (enExample)
KR (1) KR20100035648A (enExample)
CN (1) CN101835891A (enExample)
AP (1) AP2010005103A0 (enExample)
AU (1) AU2008266885A1 (enExample)
CA (1) CA2690143A1 (enExample)
CO (1) CO6251330A2 (enExample)
EA (1) EA201070022A1 (enExample)
IL (1) IL202445A0 (enExample)
MX (1) MX2009013672A (enExample)
NZ (1) NZ582616A (enExample)
WO (1) WO2008156728A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969980B2 (en) * 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US9969977B2 (en) * 2002-09-20 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
EA201070022A1 (ru) 2007-06-15 2010-06-30 Гарнет Байотерапьютикс Инк. Лечение заболеваний и нарушений с использованием самообновляющихся образующих колонии клеток, культивированных и размноженных in vitro
EP2418484A4 (en) * 2009-04-06 2012-09-05 Univ Yeungnam Iacf METHOD FOR PRODUCTION OF SPECIFIC SERUM OF THE SEX AND BIOMARKER USING THE SERUM
MX2012013800A (es) * 2010-05-28 2014-01-31 Garnet Biotherapeutics Inc Composiciones y metodos para usar dispositivos bioactivos vivientes y no vivientes con componentes derivados de celulas formadoras de colonias de auto-renovacion cultivadas y expandidas in vitro.
EP2554662A1 (en) * 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
KR101548124B1 (ko) * 2011-10-04 2015-08-31 (주) 메디컬그룹베스티안 피부결함의 완화 또는 치료를 위한 세포처리 및 적용 시스템
US10016458B2 (en) 2012-04-16 2018-07-10 Baystate Health, Inc. p53 silenced endothelial progenitor cells for diabetes
US20140134732A1 (en) * 2012-11-14 2014-05-15 Wisconsin Alumni Research Foundation Simplified Compositions and Methods for Generating Neural Stem Cells From Human Pluripotent Stem Cells
GB201513996D0 (en) 2015-08-07 2015-09-23 Cell Therapy Ltd Immuno-oncology mesodermal progenitor (IOMP) cell
US10463767B2 (en) 2016-04-22 2019-11-05 Vivex Biologics Group, Inc. Moldable bone composition
US11253630B2 (en) 2016-04-22 2022-02-22 Vivex Biologics Group, Inc. Malleable demineralized bone composition and method of manufacture
US10596298B2 (en) 2016-04-22 2020-03-24 Vivex Biologics Group, Inc. Malleable demineralized bone composition and method of manufacture
US9788950B1 (en) 2016-04-22 2017-10-17 Vivex Biomedical, Inc. Cohesive bone composition
US11253629B2 (en) 2016-04-22 2022-02-22 Vivex Biologics Group, Inc. Bone gel sheet composition and method of manufacture
US20210088505A1 (en) * 2017-04-07 2021-03-25 La Jolla Institute For Allergy And Immunology Unipotent Neutrophil Progenitor Cells, Methods of Preparation, and Uses Thereof
CN109251885A (zh) * 2018-09-26 2019-01-22 北京添易医学研究院 医美级胎盘基蜕膜干细胞内液的制备方法
CN111394306B (zh) * 2020-04-15 2023-08-01 深圳市旷逸生物科技有限公司 一种提高脐带间充质干细胞的体外扩增速率的培养方法
CN114591910B (zh) * 2022-03-28 2023-11-21 重庆市铂而斐细胞生物技术有限公司 一种利用低氧三维环境培养的间充质干细胞富集脐血造血干细胞的方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1168205B (it) 1983-07-21 1987-05-20 Wellcome Italia Derivato di monsialo ganglioside dotato di attivita' antibatterica, antifungina ed antitumorale, composizioni che lo contengono e procedimento per la loro preparazione
US4609551A (en) 1984-03-20 1986-09-02 Arnold Caplan Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites
US4608199A (en) 1984-03-20 1986-08-26 Arnold Caplan Bone protein purification process
US4620327A (en) 1984-07-05 1986-11-04 Caplan Arnold I Process of adapting soluble bone protein for use in stimulating osteoinduction
US5744347A (en) * 1987-01-16 1998-04-28 Ohio University Edison Biotechnology Institute Yolk sac stem cells and their uses
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US6010696A (en) 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5226914A (en) 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5811094A (en) 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US5733542A (en) 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
ATE247933T1 (de) 1994-06-06 2003-09-15 Univ Case Western Reserve Biomatrix für geweberegenaration
US6174333B1 (en) 1994-06-06 2001-01-16 Osiris Therapeutics, Inc. Biomatrix for soft tissue regeneration using mesenchymal stem cells
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5643736A (en) 1995-02-06 1997-07-01 Osiris Therapeutics, Inc. Monoclonal antibodies for human osteogenic cell surface antigens
US6974571B2 (en) 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US6653134B2 (en) 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
US5716616A (en) 1995-03-28 1998-02-10 Thomas Jefferson University Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects
US5728581A (en) 1995-06-07 1998-03-17 Systemix, Inc. Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein
CN1209836A (zh) 1995-12-29 1999-03-03 阿尔格公司 骨髓基质细胞的扩展
US5811297A (en) * 1996-03-07 1998-09-22 Amba Biosciences, Llc Immortalized hematopoietic cell lines, cell system thereof with stromal cells, in vitro, ex vivo and in vivo uses, & in vitro generation of dendritic cells and macrophages
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
AU3888699A (en) 1998-05-07 1999-11-23 University Of South Florida Bone marrow cells as a source of neurons for brain and spinal cord repair
WO2000024261A1 (en) 1998-10-26 2000-05-04 Philadelphia Health & Education Corporation Stromal cell use
US6184035B1 (en) 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
US20030003572A1 (en) 1999-03-05 2003-01-02 David J. Anderson Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression
CA2373808C (en) 1999-05-14 2011-04-19 Henry Ford Health System Bone marrow transplantation for treatment of central nervous system damage
US6226914B1 (en) * 1999-06-25 2001-05-08 Waymon Burton Reed Firearm safety apparatus
AUPQ147799A0 (en) * 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US8075881B2 (en) 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
HK1049350B (en) 1999-08-05 2012-01-27 Abt Holding Company Multipotent adult stem cells and methods for isolation
WO2001021767A2 (en) 1999-09-24 2001-03-29 Morphogen Pharmaceuticals, Inc. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
JP2003513648A (ja) 1999-10-29 2003-04-15 フイラデルフイア・ヘルス・アンド・エデユケーシヨン・コーポレーシヨン ヒト骨髄ストローマ細胞の単離および拡張
FR2801979B1 (fr) 1999-12-03 2002-02-08 Oreal Utilisation d'un anticorps specifique des fibroblastes papillaires comme marqueur de qualite d'une peau
US7544509B2 (en) 2000-01-24 2009-06-09 Mcgill University Method for preparing stem cell preparations
EP1749884A1 (en) 2000-02-11 2007-02-07 Philadelphia, Health and Education Corporation Differentiation of bone marrow cells into neuronal cells and uses therefor
AU2001246894A1 (en) 2000-04-11 2001-10-23 Kyowa Hakko Kogyo Co. Ltd. Alpha1,2-fucosyltransferase and process for producing fucose-containing complex carbohydrate
AU2001257030A1 (en) 2000-04-12 2001-10-30 Children's Hospital Of Philadelphia Therapeutic uses for mesenchymal stromal cells
WO2002018401A2 (en) 2000-09-01 2002-03-07 Neuronyx, Inc. Novel synthetic gangliosides
AU2002224444A1 (en) 2000-10-24 2002-05-06 Children's Hospital Of Philadelphia Therapeutic uses for mesenchymal stromal cells
EP1367899A4 (en) 2001-02-14 2004-07-28 Leo T Furcht TOTIPOTENT ADULT STEM CELLS, SOURCES OF SUCH CELLS, METHODS FOR OBTAINING AND MAINTAINING SAME, METHODS FOR DIFFERENTIATING THESE CELLS, METHODS OF USING SAME, AND CELLS DERIVED FROM THE ABOVE-MENTIONED CELLS
US7056738B2 (en) 2001-03-23 2006-06-06 Tulane University Early stage multipotential stem cells in colonies of bone marrow stromal cells
US20030003090A1 (en) 2001-05-31 2003-01-02 Prockop Darwin J. Directed in vitro differentiation of marrow stromal cells into neural cell progenitors
US20030059941A1 (en) 2001-06-14 2003-03-27 Prockop Darwin J. Transduced marrow stromal cells
US20030017587A1 (en) 2001-07-18 2003-01-23 Rader William C. Embryonic stem cells, clinical applications and methods for expanding in vitro
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US9969977B2 (en) 2002-09-20 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US20060251630A1 (en) * 2002-12-24 2006-11-09 An-Go-Gen Inc. Encapsulated cell therapy
US20060288431A1 (en) 2003-02-13 2006-12-21 Norio Nakatsuji Marker for undifferentiated state of cell and composition and method for separation and preparation of stem cells
WO2005093044A1 (en) * 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
CA2566561C (en) * 2004-06-04 2013-01-08 Universite Pierre Et Marie Curie - Paris Vi A method for producing red blood cells
JP2008501724A (ja) * 2004-06-11 2008-01-24 ヴィクトリアン ティッシュ エンジニアリング センター プロプライアトリー リミテッド 組織材料およびマトリックス
AU2005302469A1 (en) * 2004-10-28 2006-05-11 Medivas, Llc Bioactive wound dressings and implantable devices and methods of use
EA201070022A1 (ru) 2007-06-15 2010-06-30 Гарнет Байотерапьютикс Инк. Лечение заболеваний и нарушений с использованием самообновляющихся образующих колонии клеток, культивированных и размноженных in vitro

Also Published As

Publication number Publication date
US20140099329A1 (en) 2014-04-10
US20090053183A1 (en) 2009-02-26
AU2008266885A1 (en) 2008-12-24
CN101835891A (zh) 2010-09-15
US8354370B2 (en) 2013-01-15
NZ582616A (en) 2012-07-27
CO6251330A2 (es) 2011-02-21
US20120156192A1 (en) 2012-06-21
IL202445A0 (en) 2011-08-01
AP2010005103A0 (en) 2010-02-28
EP2171043A1 (en) 2010-04-07
JP2010529987A (ja) 2010-09-02
US20120148544A1 (en) 2012-06-14
EA201070022A1 (ru) 2010-06-30
EP2171043B1 (en) 2015-03-18
EP2171043A4 (en) 2010-08-11
CA2690143A1 (en) 2008-12-24
US20140086884A1 (en) 2014-03-27
WO2008156728A1 (en) 2008-12-24
KR20100035648A (ko) 2010-04-05

Similar Documents

Publication Publication Date Title
MX2009013672A (es) Tratamiento de enfermedades y trastornos utilizando celulas formadoras de colonias de autorenovacion cultivadas y expandidas in vitro.
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
UA101493C2 (ru) Производные азетидина и циклобутана как ингибиторы jak
IL250832B (en) A mixture of beta-glycosylceramide and beta-lactosylceramide for use in the treatment of colitis
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
EP2350129A4 (en) PD1 Antagonist Compositions and Methods for their Use
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
MY173994A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
AU2007257423A8 (en) Purine analogs
UA107573C2 (xx) LACTOBACILLUS JOHNSONII La1 NCC533 (CNCM I-1225) І ІМУННІ РОЗЛАДИ
ZA200702322B (en) Compositions and methods for the diagnosis and treatment of tumor
PH12012500620A1 (en) Compounds
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
UA90048C2 (ru) Кондиционированная композиция и способ ее получения
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
NZ589311A (en) Angiogenin-enriched milk fractions prepared by methods involving heating the milk to over 70 degrees celsius for at least one minute
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
MX2011012505A (es) Piperidinas sustituidas.
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
GEP20115332B (en) Herbal composition for inflammatory disorders
TW200745132A (en) Novel, acyclically substituted furopyrimidine derivatives and use thereof

Legal Events

Date Code Title Description
FG Grant or registration